International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
Stefan Zeuzem, Jean–Michel Pawlotsky, Esther Lukasiewicz et al. · Journal of Hepatology · 2005
Cited by 146 works. doi:10.1016/j.jhep.2005.05.016
Authors
- Stefan Zeuzem
- Jean–Michel Pawlotsky
- Esther Lukasiewicz
- Michael Wagner
- Ioannis Goulis
- Yoav Lurie
- Gianfranco Elia
- Jan-Maarten Vrolijk
- Juan Ignacio Esteban
- Christophe Hézode
- Martin Lagging
- Francesco Negro
- Elke Verheij‐Hart
- Bettina E. Hansen
- Ronen Tal
- Carlo I. Ferrari
- Solko Walle Schalm
- Avidan Uriel Neumann
- for the DITTO-HCV Study Group
References
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
- Allocation of Patients to Treatment in Clinical Trials
- EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2
- Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a
- National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10-12, 2002
- Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C Virus